Induction Chemotherapy to Downstage Advanced Oesophageal Cancer Before Surgery
the Cancer Therapy Advisor take:
After diagnosis of locoregionally advanced oesophageal tumors or disputable distant metastases, patients receive induction chemotherapy. The aim of chemotherapy in these patients is to downstage the tumor. After induction chemotherapy is complete and tumor size is reduced, oesophagectomy can be an option.
Researchers used an institution’s database to identify patients who received induction chemotherapy between January 2005 and December 2012. A multidisciplinary team created a treatment plan and the patient’s response to induction chemotherapy was assessed by CT. The Kaplan Meier method was used to calculate survival and the researchers performed univariable and multivariable analyses to find prognostic factors for survival.
The study included 124 patients with oesophageal tumors who were treated with induction chemotherapy. The patients were mainly treated for locoregionally advanced disease (80 patients). If the disease progressed after chemotherapy surgery was not an option (16 patients). Nineteen patients did not receive surgery because of persistent unresectability.
The median overall survival of these patients was 12 months. Eighty-nine patients were eligible for and underwent surgery and 13 were found to have unresectable tumors or distant metastases. Seventy-six patients were treated with oesophagectomy, 50 of those patients had tumor-free resection margins and were estimated to have a 5-year survival of 37%.
The researchers found, after univariable analysis, that a positive resection margin was associated with worse survival rates. Multivariable analysis, however, revealed that only pathological lymph node status with increasing hazard ratios was significant in relation to overall survival.
After diagnosis of locoregionally advanced oesophageal tumors or disputable distant metastases, patients receive induction chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia